Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Nebulized versus subcutaneous epinephrine for severe acute asthma attacks in children
IRCT20230606058389N1Phase 2Completed
- Sponsor
- Mashhad University of Medical Sciences
- Start
- Jul 2023
- Modality
- Small Molecules, Recombinant Proteins and Enzymes
- Countries
- 1
01
Overview
Phase 2, open-label trial of epinephrine in asthma and status asthmaticus (2 arms), sponsored by Mashhad University of Medical Sciences. Primary endpoints: Respiratory rate, Wheeze and 4 more. Started Jul 2023; status: completed.
02
Drugs
epinephrine
03
Conditions
asthmastatus asthmaticus
Beyond the preview
Go deeper on IRCT20230606058389N1.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on IRCT20230606058389N1.